Preparation, characterization and anti-angiogenesis activity of endostatin covalently modified by polysulfated heparin

Pharmazie

Volumn 67, Issue 7, 2012, Pages 622-627

  Ning, Tan Hai ^a   Chao, Cao Ji ^a   Ying, Mu Guo ^a   Min, Xiao ^a   Shan, Wang Feng ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; ENDOSTATIN; HEPARIN DERIVATIVE; PIGMENT EPITHELIUM DERIVED FACTOR; POLYSULFATED HEPARIN; UNCLASSIFIED DRUG; VASCULOTROPIN; AMINO ACID; ANGIOGENESIS INHIBITOR; DRUG DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; EYE PROTEIN; HEPARIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CHEMICAL MODIFICATION; CHORIOALLANTOIS; CHOROID; CIRCULAR DICHROISM; CONTROLLED STUDY; COVALENT BOND; DRUG CONJUGATION; DRUG EFFECT; DRUG FORMULATION; DRUG INHIBITION; DRUG PURITY; DRUG STABILITY; DRUG SYNTHESIS; EMBRYO; ENDOTHELIUM CELL; HEAT TOLERANCE; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECONDARY STRUCTURE; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RETINA NEOVASCULARIZATION; THERMOSTABILITY; WESTERN BLOTTING; ANGIOGENESIS; ANIMAL; BIOSYNTHESIS; CHEMISTRY; CHICK EMBRYO; HEAT; LASER; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS;

AMINO ACIDS; ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CHICK EMBRYO; CHOROID; CIRCULAR DICHROISM; DRUG STABILITY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOSTATINS; EYE PROTEINS; HEPARIN; HOT TEMPERATURE; INDICATORS AND REAGENTS; LASERS; NEOVASCULARIZATION, PHYSIOLOGIC; NERVE GROWTH FACTORS; SERPINS; TETRAZOLIUM SALTS; THIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865631978     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1135     Document Type: Article

References (28)

1. Abdollahi A, Hlatky L, Huber PE (2005) Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat 8: 59-74.
2. Cao QZ, Lin ZB (2004) Antitumor and anti-angiogenic activity of Ganoderma lucidum polysaccharides peptide. Acta Pharmacol Sin 25: 833-838.
3. Chen DQ, Wang X, Chen L, He JX, Miao ZH, Shen JK (2011) Novel liver-specific cholic acid-cytarabine conjugates with potent antitumor activities: Synthesis and biological characterization. Acta Pharmacol Sin 32: 664-672.
4. Cui XZ, Xu HL, Zhou S, Zhao T, Liu AH, Guo XP, Tang W, Wang FS (2009) Evaluation of angiogenic activities of hyaluronan oligosaccharides of defined minimum size. Life Sci 85: 573-577.
5. Folkman J (2006) Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312: 594-607.
6. Habeeb AF (1966) Determination of free amina groups in protein by trintrobenzennesulfonic acid. Anal Biochem 14: 328-336.
7. Han DW, Lee MH, Kim HH, Hyon SH, Park JC (2011) Epigallocatechin-3- gallate regulates cell growth, cell cycle and phosphorylated nuclear factor-κB in human dermal fibroblasts. Acta Pharmacol Sin 32: 637-646.
8. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL (2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20: 3792-3803.
9. Hohenester E, Sasaki T, Olsen BR, Timpl R (1998) Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J 17: 1656-1664.
10. Hu B, Zhu HW, Zhu LP, Li C, Rong ZG, Xu JM, Wu ZW, Wang JJ, Xu GX (2008) Bioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin1. Acta Pharmacol Sin 29: 1357-1369.
11. Ji SL, Du HY, Chi YQ, Cui HF, Cao JC, Geng MY, Guan HS (2004) Effects of dermatan sulfate derivatives on platelet surface P-selectin expression and protein C activity in blood of inflammatory bowel disease patients. World J Gastroenterol 10: 3485-3489.
12. Kodama K, Nakayama H, Sakamoto K, Fukuzawa S, Kigawa T, Yabuki T, Kitabatake M, Takio K, Yokoyama S (2010) Site-specific incorporation of 4-iodo-L-phenylalanine through opal suppression. J Biochem 148: 179-187.
13. Li C, Zhang F, Lin H,Wang ZC, Liu XJ, Feng ZQ, Zhu J, Guan XH (2011) Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus. Acta Pharmacol Sin 32: 329-337.
14. Mori K, Ando A, Gehlbach P, Nesbitt D, Takahashi K, Goldsteen D, Penn M, Chen CT, Mori K, Melia M, Phipps S, Moffat D, Brazzell K, Liau G, Dixon KH, Campochiaro PA (2001) Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 159: 313-320.
15. Nie Y, Zhang X, Wang X, Chen J (2006) Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin. Bioconjug Chem 17: 995-999.
16. NorrbyK(2006) Low-molecular-weight heparins and angiogenesis. APMIS 114: 79-102.
17. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiognesis and tumor growth. Cell 88: 277-285.
18. Sasaki T, Fukai N, Mann K, GoringW, Olsen BR, Timpl R (1998) Structure, function and tissue forms of the Cterminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 17: 4249-4256.
19. Sato Y (2011) Is vasohibin-1 for more than angiogenesis inhibition. J Biochem 149: 229-230.
20. Tam SC, Blumenstein J, Wong JT (1976) Soluble dextran-hemoglobi complex as a potential blood substitute. P Natl Acad Sci USA 73: 3128-3131.
21. Tan HN, Mu GY, Zhu W, Liu JF, Wang FS (2011) Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug. Biol Pharm Bull 34: 545-550.
22. Tan HN, Yang SL, Feng Y, Liu CH, Cao JC, Mu GY,Wang FS (2008) Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin. J Biochem 144: 207-213.
23. Whitmore L, Wallace BA (2008) Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases. Biopolymers 89: 392-400.
24. Yoshida T, Yasuda Y, Mimura T, Kaneko Y(1995) Synthesis of curdlan sulfates having inhibitory effects in vitro against AIDS viruses HIV-1 and HIV-2. Carbohyd Res 276: 425-436.
25. You W K, So SH, Lee H, Park SY, Yoon MR, Chang SI, Kim HK, Joe YA, Hong YK, Chung SI (1999) Purification and characterization of recombinant murine endostatin in E. coli. Exp Mol Med 31: 197-202.
26. Zhang HW, Wang FS, Shao W, Zheng XL, Qi JZ, Cao JC, Zhang TM (2006) Characterization and stability investigation of cu,zn-superoxide dismutase covalently modified by low molecular weight heparin. Biochemistry-Moscow 71: S96-100.
27. Zhu B, Xu HM, Zhao L, Huang X, Zhang F(2010) Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa. J Biochem 148: 341-347.
28. Zugmaier G, Favoni R, Jaeger R, Rosen N, Knabbe C (1999) Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors. Ann NY Acad Sci 886: 243-248.